# Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct01522651` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01522651](<https://clinicaltrials.gov/study/NCT01522651>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01522651

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 134 participants.

## Technical summary

Registry record NCT01522651. Randomized; double masking; primary purpose treatment. Start 2012-01-24 (actual); primary completion 2014-03-10 (actual). Results posted on 2020-11-06.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 134 participants (enrolled count; ClinicalTrials.gov record NCT01522651, source copy `cardio:ctgov-nct01522651-2020-11-06`, retrieved 2026-10-26)
- Started: 2012-01-24 (actual) (ClinicalTrials.gov record NCT01522651, source copy `cardio:ctgov-nct01522651-2020-11-06`, retrieved 2026-10-26)
- Primary completion: 2014-03-10 (actual) (ClinicalTrials.gov record NCT01522651, source copy `cardio:ctgov-nct01522651-2020-11-06`, retrieved 2026-10-26)
- Completion: 2014-03-10 (actual) (ClinicalTrials.gov record NCT01522651, source copy `cardio:ctgov-nct01522651-2020-11-06`, retrieved 2026-10-26)
- Results first posted: 2020-11-06 (ClinicalTrials.gov record NCT01522651, source copy `cardio:ctgov-nct01522651-2020-11-06`, retrieved 2026-10-26)
- Countries: United States; Germany; Israel; Italy; Netherlands; Poland; United Kingdom (ClinicalTrials.gov record NCT01522651, source copy `cardio:ctgov-nct01522651-2020-11-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01522651-2020-11-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
- Acronym: HARMONY
- Condition: Atrial Fibrillation
- Intervention (Drug): Ranolazine
- Intervention (Drug): Dronedarone
- Intervention (Drug): Ranolazine placebo
- Intervention (Drug): Dronedarone placebo
- Lead sponsor: Gilead Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Gilead Sciences (`cardio:org-gilead-sciences`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism (`cardio:pubmed-26226999`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f4188de39d36c09e4c8d07e7718c38864eaca7a070201088ecad5f2f39c7b499
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
